JPWO2020041658A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020041658A5 JPWO2020041658A5 JP2021509982A JP2021509982A JPWO2020041658A5 JP WO2020041658 A5 JPWO2020041658 A5 JP WO2020041658A5 JP 2021509982 A JP2021509982 A JP 2021509982A JP 2021509982 A JP2021509982 A JP 2021509982A JP WO2020041658 A5 JPWO2020041658 A5 JP WO2020041658A5
- Authority
- JP
- Japan
- Prior art keywords
- capsaicin
- knee
- dose
- administered
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 760
- 229960002504 capsaicin Drugs 0.000 claims description 378
- 235000017663 capsaicin Nutrition 0.000 claims description 378
- 210000003127 knee Anatomy 0.000 claims description 252
- 208000002193 Pain Diseases 0.000 claims description 196
- 238000001816 cooling Methods 0.000 claims description 138
- 210000000629 knee joint Anatomy 0.000 claims description 87
- 239000008194 pharmaceutical composition Substances 0.000 claims description 76
- 238000002347 injection Methods 0.000 claims description 54
- 239000007924 injection Substances 0.000 claims description 54
- 208000006820 Arthralgia Diseases 0.000 claims description 37
- 239000003589 local anesthetic agent Substances 0.000 claims description 31
- 239000012530 fluid Substances 0.000 claims description 30
- 210000001519 tissue Anatomy 0.000 claims description 28
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 26
- 229960004194 lidocaine Drugs 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 25
- 230000001747 exhibiting effect Effects 0.000 claims description 20
- 239000002202 Polyethylene glycol Substances 0.000 claims description 16
- 201000008482 osteoarthritis Diseases 0.000 claims description 16
- 229920001223 polyethylene glycol Polymers 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 208000003947 Knee Osteoarthritis Diseases 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 239000007972 injectable composition Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 150000007513 acids Chemical class 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 150000002334 glycols Chemical class 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 347
- 239000000105 vanilloid receptor agonist Substances 0.000 description 10
- -1 polyethylene Polymers 0.000 description 7
- 206010006784 Burning sensation Diseases 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 230000001052 transient effect Effects 0.000 description 5
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229960002860 zucapsaicin Drugs 0.000 description 2
- YKPUWZUDDOIDPM-VURMDHGXSA-N zucapsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C/C(C)C)=CC=C1O YKPUWZUDDOIDPM-VURMDHGXSA-N 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862722396P | 2018-08-24 | 2018-08-24 | |
| US62/722,396 | 2018-08-24 | ||
| PCT/US2019/047823 WO2020041658A1 (en) | 2018-08-24 | 2019-08-23 | Capsaicin sequential dosing method for treatment of knee joint pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534207A JP2021534207A (ja) | 2021-12-09 |
| JPWO2020041658A5 true JPWO2020041658A5 (enExample) | 2024-02-13 |
Family
ID=69591314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021509982A Pending JP2021534207A (ja) | 2018-08-24 | 2019-08-23 | 膝関節痛の治療のためのカプサイシン連続投薬方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20210315846A1 (enExample) |
| EP (1) | EP3840739B1 (enExample) |
| JP (1) | JP2021534207A (enExample) |
| AU (1) | AU2019325407B2 (enExample) |
| CA (1) | CA3109932A1 (enExample) |
| WO (1) | WO2020041658A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115970142A (zh) * | 2023-02-01 | 2023-04-18 | 岳阳职业技术学院 | 一种便携式膝盖理疗装置 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE219674T1 (de) | 1997-03-13 | 2002-07-15 | James N Campbell | Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika |
| JP2006513267A (ja) | 2002-12-18 | 2006-04-20 | アルゴルクス ファーマスーティカルズ，インク | カプサイシノイドの投与 |
| US20040161481A1 (en) | 2002-12-18 | 2004-08-19 | Algorx | Administration of capsaicinoids |
| US8158682B2 (en) | 2008-09-12 | 2012-04-17 | Vallinex, Inc. | Instillation administration of capsaicinoids for the treatment of pain |
| JP6695140B2 (ja) * | 2012-11-12 | 2020-05-20 | ヴィズリ・ヘルス・サイエンスィズ・エルエルシー | 水性カプサイシノイド配合物ならびにその製造法および使用法 |
| US20150133561A1 (en) * | 2013-11-12 | 2015-05-14 | Vizuri Health Sciences Llc | Aqueous based capsaicinoid formulations and methods of manufacture and use |
| CN105848638A (zh) * | 2013-12-16 | 2016-08-10 | 硕腾服务有限责任公司 | 长效酮洛芬组合物 |
| AU2017210315A1 (en) * | 2016-01-22 | 2018-08-16 | Centrexion Therapeutics Corporation | Capsaicin sequential dosing method for treatment of morton's neuroma pain |
| JP7100635B2 (ja) * | 2016-11-02 | 2022-07-13 | セントレクシオン セラピューティクス コーポレイション | 安定な水性カプサイシン注射製剤およびその医学的使用 |
| IL272036B2 (en) * | 2017-07-20 | 2025-01-01 | Centrexion Therapeutics Corp | Methods and compositions for treating pain using capsaicin |
-
2019
- 2019-08-23 JP JP2021509982A patent/JP2021534207A/ja active Pending
- 2019-08-23 US US17/269,577 patent/US20210315846A1/en not_active Abandoned
- 2019-08-23 CA CA3109932A patent/CA3109932A1/en active Pending
- 2019-08-23 AU AU2019325407A patent/AU2019325407B2/en active Active
- 2019-08-23 WO PCT/US2019/047823 patent/WO2020041658A1/en not_active Ceased
- 2019-08-23 EP EP19851394.7A patent/EP3840739B1/en active Active
-
2024
- 2024-11-14 US US18/947,057 patent/US20250241879A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2916817B1 (en) | Aqueous based capsaicinoid formulations and methods of manufacture and use | |
| JP6117939B2 (ja) | ジクロフェナク組成物 | |
| JP2023061957A (ja) | 抑うつ障害の処置 | |
| TWI674899B (zh) | 醫藥配方 | |
| US20190142948A1 (en) | Aqueous based capsaicinoid formulations and methods of manufacture and use | |
| JP2020527574A5 (enExample) | ||
| CA2735834C (en) | Composition comprising ibuprofen and paracetamol to treat pain caused by osteoarthritis and rheumatoid arthritis | |
| IL272036B1 (en) | Methods and compositions for treatment of pain using capsaicin | |
| JP2019506397A5 (enExample) | ||
| AU2018388417B2 (en) | Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes | |
| JPWO2020041658A5 (enExample) | ||
| KR20120089444A (ko) | 정맥내 이부프로펜에 의한 위독한 환자의 치료방법 | |
| US11642328B2 (en) | Creatine, its derivatives, compositions and methods of use thereof | |
| Ehret | Haloperidol Decanoate: First-Generation Antipsychotic Long-Acting Injectable | |
| WO2000061152A1 (en) | Management of pain after joint surgery | |
| Ehret | Fluphenazine Decanoate: First-Generation Antipsychotic Long-Acting Injectable | |
| CA2243657C (en) | Compositions for treatment of erectile dysfunction | |
| WO2022178018A1 (en) | Liquid unit dosage forms for treatment of pain | |
| HK1174493A (en) | Treating critically ill patients with intravenous ibuprofen |